Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) has been assigned an average recommendation of "Buy" from the eleven brokerages that are presently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $46.56.

Several research firms recently weighed in on ZNTL. Oppenheimer cut their price target on shares of Zentalis Pharmaceuticals from $80.00 to $50.00 and set an "outperform" rating on the stock in a report on Thursday, November 10th. Wedbush cut their price target on shares of Zentalis Pharmaceuticals from $51.00 to $32.00 and set an "outperform" rating on the stock in a report on Monday, November 14th. Morgan Stanley cut their price target on shares of Zentalis Pharmaceuticals from $60.00 to $55.00 and set an "overweight" rating on the stock in a report on Friday, November 11th. SVB Leerink cut their price target on shares of Zentalis Pharmaceuticals from $42.00 to $27.00 and set an "outperform" rating on the stock in a report on Thursday, November 10th. Finally, Guggenheim cut their price target on shares of Zentalis Pharmaceuticals from $55.00 to $28.00 and set a "buy" rating on the stock in a report on Friday, November 11th.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, President Cam Gallagher sold 12,500 shares of the business's stock in a transaction dated Monday, November 7th. The shares were sold at an average price of $23.67, for a total value of $295,875.00. Following the transaction, the president now directly owns 396,885 shares in the company, valued at $9,394,267.95. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 50,000 shares of company stock worth $1,153,375 over the last three months. 19.90% of the stock is currently owned by insiders.

Institutional Trading of Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Price Performance

NASDAQ:ZNTL opened at $18.28 on Friday. The firm has a 50-day moving average of $21.55 and a 200-day moving average of $24.69. The company has a market cap of $1.04 billion, a PE ratio of -3.87 and a beta of 1.80. Zentalis Pharmaceuticals has a one year low of $17.33 and a one year high of $85.95.

Zentalis Pharmaceuticals Company Profile

(Get Rating)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.

Featured Articles

• Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
• MarketBeat: Week in Review 12/19 – 12/23
• These Steelmakers Deserve A Place On Your 2023 Watch List
• Inflation Cools, Where Does The S&P 500 Go Now
• Cintas Beats Inflation With Operating Leverage
• Your Decision to Buy Palantir May Simply Be a Matter of Time

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.